Loading clinical trials...
Loading clinical trials...
The purpose of this study is to determine the maximum tolerated dose (MTD) of BMS-833923 administered in combination with carboplatin and etoposide followed by BMS-833923 alone in subjects with extens...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Bristol-Myers Squibb
Collaborators
NCT06992609 · Small Cell Lung Carcinoma
NCT07144280 · Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic, and more
NCT04585750 · Advanced Solid Tumor, Advanced Malignant Neoplasm, and more
NCT07046923 · Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, and more
NCT06772623 · Non Small Cell Lung Carcinoma
Karmanos Cancer Institute
Detroit, Michigan
Local Institution
East Bentleigh, Victoria
Local Institution
Edmonton, Alberta
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions